Assessment of impact on quality of life in patients with rheumatoid arthritis of the use of combined triple therapy methotrexate, lefluno- mide and wobenzym The aim ofthe study was to assess the quality of life of patients with rheu- matoid arthritis (RA) in the appointment of a triple combination therapy with methotrexate (MT), leflunomide (LF) and Wobenzym (WFB). During the study period, patients in both groups showed improved functional status. In the group with triple therapy, the average HAQ decreased from 1,5 to 0,5, and in the monotherapy group, the MT and LF – from 2,5 to 2,0 and 0,75 points (p = 0,008). The number of patients with minimal disruption to functional status (HAQ of 0 to 1.0), moderate (HAQ 1,1 to 2,0) and severe (HAQ 2,1 to 3,0) at the end of the study in both groups was similar. Thus, the original between-group differences in functional improvement was observed. All types of therapy reduced the average daily doses of corticosteroids, together with 5,0 to 2,5 mg (all groups) and NSAIDs were abolished in 76% of patients receiving triple therapy, and approximately 50% with MT and LF alone. Thus, intergroup differences were observed in the reduction of inflammatory syndrome in triple DMARD therapy.